If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business. Looking at the Pfizer stock split history from start to finish, an original position size of shares would have turned into today. If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Pfizer Stock Split History www. Stock Split History. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person.
Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies , and Mergent. Free Dividend Report. PFE Dividend History. Preferred Stock Newsletter. PFE Options Chain. Second, the company's revenue and net income growth has been stuck in the mud for many years as it has dealt with the loss of patent protection on several important drugs.
When combined, these factors have kept a lid on the company's share price appreciation, which has negated the need for the company to perform a stock split. While the last two decades haven't been great for Pfizer's shareholders, there are ample reasons to believe the future is looking bright. First, Pfizer's financials look poised for steady growth over the coming years thanks to the continued growth of a few recently launched blockbusters.
Included in this list is a next-generation blood thinner called Eliquis that is being co-marketed with Bristol-Myers Squibb.
Two other recent winners include breast cancer drug Ibrance and rheumatoid arthritis drug Xeljanz. Second, Pfizer's pipeline also offers investors reason for hope. The company believes it could launch 15 potential blockbusters drugs in the next five years alone. For perspective, Pfizer only brought five new blockbuster drugs to market over the past half-century, so the pipeline provides a lot of reason for optimism. Finally, Pfizer's current valuation isn't pricing in a lot of growth.
What's more, income investors will also like that this company's dividend yield tops 3. All in all, Pfizer looks like an attractive value stock right, even though the company probably won't need to split its stock anytime soon. Discounted offers are only available to new members. Stock Advisor will renew at the then current list price. Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Investing Best Accounts. Stock Market Basics. Pfizer Quarterly Stock Splits. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products.
Pfizer's Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals.
It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. We Need Your Support!
0コメント